Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trialsL. A. Smith, Alison Jones, Victoria Cornelius et al.|BMC Cancer|2010Cited by 755
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac riskPeter Barrett‐Lee, Mark Verrill, Renaud Léonard et al.|Annals of Oncology|2009Cited by 198
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety reportAlicia Okines, David Cunningham, Ruth E. Langley et al.|Annals of Oncology|2012Cited by 67
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo G. Tocchetti, Teresa López‐Fernández, Alexander R. Lyon et al.|European Journal of Heart Failure|2024Cited by 64